Investment Considerations Quantum BioPharma is advancing a clinical-stage multiple sclerosis program targeting demyelination, a differentiated approach compared to many existing therapies focused primarily on immune modulation. The company maintains royalty participation and equity ownership exposure to unbuzzd™ while preserving pharmaceutical and medical-use rights to related formulations. Lucid-MS has completed Phase 1 safety studies and advanced … Continue reading “Quantum BioPharma Ltd. (NASDAQ: QNTM)”
| Symbol | Release | Time |
|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |